Drug
Met XR
Met XR is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Phase Distribution
Ph phase_1
1
25%
Ph phase_3
1
25%
Ph phase_2
2
50%
Phase Distribution
1
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women
NCT02338193
completedphase_2
Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
NCT01819272
completedphase_1
Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects
NCT02291510
completedphase_2
Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction
NCT01658514
Clinical Trials (4)
Showing 4 of 4 trials
NCT02338193Phase 3
Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women
NCT01819272Phase 2
Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
NCT02291510Phase 1
Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects
NCT01658514Phase 2
Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4